Cargando…

Comparison of Antithrombin III and Pentoxifylline Treatments in Gram Negative Sepsis Patients Developing Disseminated Intravascular Coagulation

OBJECTIVE: The aim of this study was to evaluate the effects of antithrombin III (AT III) and pentoxifylline treatments on the gram negative septic patients with disseminated intravascular coagulation (DIC). METHOD: For six days after plasma AT III activity dropped lower than 80% in Gram-patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozden, Mesure Gul Nihan, Koksal, Guniz, Oz, Huseyin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Istanbul Medeniyet University 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433740/
https://www.ncbi.nlm.nih.gov/pubmed/32821443
http://dx.doi.org/10.5222/MMJ.2019.05935
_version_ 1783572015275311104
author Ozden, Mesure Gul Nihan
Koksal, Guniz
Oz, Huseyin
author_facet Ozden, Mesure Gul Nihan
Koksal, Guniz
Oz, Huseyin
author_sort Ozden, Mesure Gul Nihan
collection PubMed
description OBJECTIVE: The aim of this study was to evaluate the effects of antithrombin III (AT III) and pentoxifylline treatments on the gram negative septic patients with disseminated intravascular coagulation (DIC). METHOD: For six days after plasma AT III activity dropped lower than 80% in Gram-patients who developed DIC were treated with AT III (90-120 IU/kg/day in 6 hours) or pentoxifylline (1.5 mg/kg/h in 6 hours) Fibrinogen, FDP, D-dimer, complete blood count, AT III activity, and DIC scores were calculated and recorded. RESULTS: The coagulation tests, AT III activity and FDP started to improve from the second day of treatment with both treatments (p<0.05). D-Dimer started to decrease on the second day of treatment with pentoxifylline (p<0.001) and fourth day of AT III treatment (p<0.05). Fibrinogen levels decreased on the second day of pentoxifylline treatment (p<0.05) and on the last day of AT III treatment (p<0.001). DIC scores started to decrease on the last day of treatment with AT III treatment (p<0.001) and on the third day of treatment with pentoxifylline (p<0.05). CONCLUSION: Both ATIII and pentoxifylline treatments had positive effects on fibrinogen, FDP, D-Dimer, AT III activity and DIC scores in patients with Gram-negative sepsis who developed DIC.
format Online
Article
Text
id pubmed-7433740
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Istanbul Medeniyet University
record_format MEDLINE/PubMed
spelling pubmed-74337402020-08-19 Comparison of Antithrombin III and Pentoxifylline Treatments in Gram Negative Sepsis Patients Developing Disseminated Intravascular Coagulation Ozden, Mesure Gul Nihan Koksal, Guniz Oz, Huseyin Medeni Med J Original Study OBJECTIVE: The aim of this study was to evaluate the effects of antithrombin III (AT III) and pentoxifylline treatments on the gram negative septic patients with disseminated intravascular coagulation (DIC). METHOD: For six days after plasma AT III activity dropped lower than 80% in Gram-patients who developed DIC were treated with AT III (90-120 IU/kg/day in 6 hours) or pentoxifylline (1.5 mg/kg/h in 6 hours) Fibrinogen, FDP, D-dimer, complete blood count, AT III activity, and DIC scores were calculated and recorded. RESULTS: The coagulation tests, AT III activity and FDP started to improve from the second day of treatment with both treatments (p<0.05). D-Dimer started to decrease on the second day of treatment with pentoxifylline (p<0.001) and fourth day of AT III treatment (p<0.05). Fibrinogen levels decreased on the second day of pentoxifylline treatment (p<0.05) and on the last day of AT III treatment (p<0.001). DIC scores started to decrease on the last day of treatment with AT III treatment (p<0.001) and on the third day of treatment with pentoxifylline (p<0.05). CONCLUSION: Both ATIII and pentoxifylline treatments had positive effects on fibrinogen, FDP, D-Dimer, AT III activity and DIC scores in patients with Gram-negative sepsis who developed DIC. Istanbul Medeniyet University 2019 2019-09-27 /pmc/articles/PMC7433740/ /pubmed/32821443 http://dx.doi.org/10.5222/MMJ.2019.05935 Text en Copyright Istanbul Medeniyet University Faculty of Medicine. http://creativecommons.org/licenses/by-nc/4.0/ This journal is published by Logos Medical Publishing. Licenced by Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
spellingShingle Original Study
Ozden, Mesure Gul Nihan
Koksal, Guniz
Oz, Huseyin
Comparison of Antithrombin III and Pentoxifylline Treatments in Gram Negative Sepsis Patients Developing Disseminated Intravascular Coagulation
title Comparison of Antithrombin III and Pentoxifylline Treatments in Gram Negative Sepsis Patients Developing Disseminated Intravascular Coagulation
title_full Comparison of Antithrombin III and Pentoxifylline Treatments in Gram Negative Sepsis Patients Developing Disseminated Intravascular Coagulation
title_fullStr Comparison of Antithrombin III and Pentoxifylline Treatments in Gram Negative Sepsis Patients Developing Disseminated Intravascular Coagulation
title_full_unstemmed Comparison of Antithrombin III and Pentoxifylline Treatments in Gram Negative Sepsis Patients Developing Disseminated Intravascular Coagulation
title_short Comparison of Antithrombin III and Pentoxifylline Treatments in Gram Negative Sepsis Patients Developing Disseminated Intravascular Coagulation
title_sort comparison of antithrombin iii and pentoxifylline treatments in gram negative sepsis patients developing disseminated intravascular coagulation
topic Original Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433740/
https://www.ncbi.nlm.nih.gov/pubmed/32821443
http://dx.doi.org/10.5222/MMJ.2019.05935
work_keys_str_mv AT ozdenmesuregulnihan comparisonofantithrombiniiiandpentoxifyllinetreatmentsingramnegativesepsispatientsdevelopingdisseminatedintravascularcoagulation
AT koksalguniz comparisonofantithrombiniiiandpentoxifyllinetreatmentsingramnegativesepsispatientsdevelopingdisseminatedintravascularcoagulation
AT ozhuseyin comparisonofantithrombiniiiandpentoxifyllinetreatmentsingramnegativesepsispatientsdevelopingdisseminatedintravascularcoagulation